You make some interesting points, but a few of them have me a little perplexed. Perhaps you are more easily pleased than most. To begin, I would hardly call over 15 years 'fledgling start up technology'. The end-game has always been integrated/advanced products and/or an integrated, high-end & personalised refillable applicator...still waiting on both fronts there; and you can X that by two (or more) if you include Coty.
'We also need to contextualise success with OBJs financials. A single modest revenue stream is sufficient to make it cash-flow positive. Cash-flow positiveness is the unattainable holy grail that most Aussie specky tech company CEOs can only dream of (and never achieve).....'
You can 'contexualise' all you want, but I hardly think 'the unattainable holy grail that most Aussie specky tech company CEOs can only dream of' is simply 'cash-flow positive'.........that is almost laughable. I originally invested for a company that would one day be a dividend paying stock. You can shove 'cash-flow positive' where the sun don't shine. There are plenty of your version of 'holy grail's' on the ASX that simply pay director wages, but still continually come back to Shareholders with their hand out to try to keep a nice fat buffer. How you could possibly call this scenario the 'holy grail' is beyond my comprehension; unless as I stated, you are too easily pleased.
I do agree 'P&G haven't dropped us like a hot potato' yet, but my original post from a couple of days ago highlights that P&G are than capable of doing so, without even a glance back over their shoulder; and this is exactly what happened with Swiss VMS & Teva Pharmaceuticals. I doubt whether OBJ would even let their Shareholders know, unless completely necessary as required by ASX Disclosure. Considering P&G have inked contracts, you would assume we would be informed as opposed to all the 'collaboratons' that have shifted into the void without any further whispers.
(20min delay)